DONATE

Cancer

IBEC receives funding from the prestigious Human Frontier Science Program

Illustration of a human cancer cell

The Institute for Bioengineering of Catalonia (IBEC) is participating in the international SOLFEGE project, which aims to explore how different cell types coordinate with each other through soluble factors in the tumour microenvironment. This project has been made possible thanks to funding from the Human Frontier Science Program. SOLFEGE is a consortium led by the German Cancer Research Center (DKFZ), with IBEC and the Duke University, as partners.

New advances in the fight against the most common form of lung cancer

From left to right, Fernando Martín and Joan Montero at the Faculty of Medicine and Health Sciences. / Credit: University of Barcelona

A study led by the University of Barcelona in collaboraiton with the Institute for Bioengineering of Catalonia reveals that the functional assay dynamic BH3 profiling (DBP) can predict whether specific treatments will be effective in non-small cell lung cancer patients. The technique helps determine which therapy will be most effective by testing it directly on living cells, improving personalised therapies.

Novel nanomotors improve bladder cancer immunotherapy

A study led by the Institute for Bioengineering of Catalonia (IBEC) and Pohang University of Science and Technology (POSTECH) in South Korea describes the development of urea-powered nanomotors that improve immunotherapy for bladder cancer. The nanomotors activate the immune system more efficiently and exceed the efficacy of currently used treatments, opening up new possibilities in oncology.

IBEC spin-off Nanobots Therapeutics receives IMPACTO grant from the Spanish Association Against Cancer

IBEC spin-off Nanobots Therapeutics has been selected in the AECC’s 2024 call for IMPACTO grants. This is an initiative of the Spanish Association Against Cancer (AECC) aimed at technology-based micro-enterprises and SMEs to accelerate the arrival of new treatments in the clinic. The grants were awarded in Barcelona today.

Researchers develop a device that replicates tumours to study the efficacy of immunotherapy treatments

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to treatment. The device, which has already been successfully tested on breast cancer samples, could be key to developing new treatments and determining the most appropriate therapy for each patient in a personalized way. The work, published in Nature Communications, is the result of a collaboration between the Institute for Bioengineering of Catalonia and the Research Institute of the Hospital del Mar.

Scientists discover how the physics of colon cancer cells contributes to metastasis

An IBEC-led study has demonstrated the ability of colorectal cancer stem cells to change their mechanical properties, facilitating the successful metastatic process. They did this using tumour organoids derived from patient cells. These findings could contribute to the development of new strategies to treat and prevent metastasis in colorectal cancer.

A study led by IBEC successfully mimics the complex neuroblastoma vasculature on a chip to explore treatments for this pediatric cancer

Two studies led by IBEC have successfully mimicked the transdifferentiation process of the neuroblastoma vasculature in in vitro models. These models, one in 2D and the other on a microfluidic chip, provide platforms for identifying new biomarkers and designing effective therapies against this type of cancer.

Nanomedicine experts gather on World Cancer Nanoday

Once again, experts in nanomedicine from various fields gathered in Barcelona on the occasion of World Cancer Day. The meeting provided an opportunity to showcase the latest innovations in nanomedicine for combating cancer, covering topics such as early diagnosis, controlled drug release, and radiotherapy employing nanoparticles.

Cookies
Cookie Consent The IBEC website uses cookies and similar technologies to ensure the basic functionality of the site and for statistical and optimisation purposes. It also uses cookies to display content such as YouTube videos that use marketing cookies. This last category consists of tracking cookies: these make it possible for your online behaviour to be tracked. You consent to this by clicking on Accept. Also read our Privacy statement. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all